Tags : m-Gastric Cancer

Pfizer’s Trazimera (trastuzumab-biosimilar) Receives FDA’s Approval for HER-2+ Breast Cancer

Shots: The approval is based on REFLECTIONS B327-02 study assessing Trazimera in 500 patients with HER2 overexpressing breast cancer & m- gastric/GEJ adenocarcinoma across 20 countries REFLECTIONS B327-02 study demonstrated a high degree of similarity & no clinical differences b/w Trazimera & Herceptin Trazimera (trastuzumab-biosimilar) is a HER2 receptor antagonist biosimilar to Herceptin and has […]Read More